Kidney disease: Proton Intelligence raises $6.95M for potassium monitoring trials

Kidney disease: Proton Intelligence raises $6.95M for potassium monitoring trials

Proton Intelligence Inc., the developer of the innovative Continuous Potassium Monitoring (CKM™) platform, has successfully closed a $6.95 million USD Seed Financing round. The round was supported by investors including SOSV, We Venture Capital, Tenmile, LongeVC, 15th Rock, Exor, and Trampoline Venture Partners. This funding will accelerate the development of Proton’s groundbreaking technology, specifically aimed at improving potassium monitoring for kidney disease patients.

Potassium plays a crucial role in managing cardio-kidney-metabolic diseases, but it is notoriously difficult to measure continuously and accurately. Potassium imbalances—whether too high (hyperkalemia) or too low (hypokalemia)—are linked to severe health risks such as cardiac arrhythmias and sudden cardiac death. Kidney disease, particularly chronic kidney disease (CKD) and end-stage renal disease (ESRD), often leads to dangerous potassium fluctuations, but there has been no way to track potassium levels consistently and in real-time.

Research reveals that approximately 33% of patients with CKD or heart failure (HF) stop essential treatments following a high potassium event, resulting in a 40% increase in 6-month mortality rates. Proton’s CKM™ technology is designed to bridge this gap by providing continuous, remote potassium monitoring, offering accurate data that will improve treatment and management of kidney-related diseases.

“At SOSV, we are proud to be the first institutional investor in Proton Intelligence,” said Mohan S. Iyer, General Partner at SOSV. “The team’s exceptional focus and relentless execution inspire confidence, and we look forward to continuing our support as Proton moves into clinical validation.”

Dr. Louise Warme, Head of We Venture Capital, added, “We are impressed with Proton’s ability to address a critical gap in electrolyte sensing. This technology has the potential to transform care for kidney disease patients at risk for dyskalemia. We’re excited to support Proton as they advance into their next phase.”

Proton Intelligence is already moving forward with clinical trials to assess the CKM™ platform’s performance in patients with severely impaired kidney function, such as those with ESRD or CKD. According to the United States Renal Data System (USRDS), 14% of U.S. adults have CKD, and this group represents over 25% of Medicare spending. ESRD patients alone account for 7% of U.S. Medicare expenditures annually, a cost that could be reduced with better potassium monitoring. Proton’s CKM™ platform can assist healthcare providers in making better, data-driven decisions for kidney disease patients, potentially lowering healthcare costs and improving outcomes.

“The ability to continuously monitor potassium will enable better management for patients with late-stage kidney disease or those on dialysis,” said Dr. Steve Burnell, Managing Director at Tenmile. “Proton’s innovation will not only improve patient outcomes but also provide significant cost savings for the healthcare system.”

Proton’s CKM™ platform aims to transform the way healthcare providers manage electrolyte imbalances in kidney disease patients. Continuous potassium monitoring will allow clinicians to adjust therapies in real-time, optimizing treatment outcomes for patients with kidney and heart disease. The platform could also help ensure the safe use of medications that may otherwise be too risky due to concerns about potassium imbalances.

“This fundraising milestone is a significant step forward for us,” said Dr. Sahan Ranamukhaarachchi, Founder and CEO of Proton Intelligence. “We’re deeply grateful for the trust and support of our investors, who share our vision of transforming kidney disease care. Their belief in our mission will enable us to complete clinical feasibility trials ahead of our pivotal study planned for 2026, getting us closer to making CKM™ a reality for millions of kidney disease patients.”

About Proton Intelligence Inc.

Proton Intelligence Inc. is based in Vancouver, Canada, with research and development operations in Melbourne, Australia. The company is revolutionizing healthcare with its continuous electrolyte monitoring technology, starting with CKM™ for potassium, which is similar to continuous glucose monitoring used in diabetes. By addressing a key challenge in managing kidney diseases, Proton is committed to enhancing patient outcomes and improving healthcare system efficiency. The company’s long-term vision includes expanding CKM™ to other critical biomarkers, improving treatments for kidney patients and beyond.

Please find the related post

Source link

Newsletter Updates

Enter your email address below and subscribe to our newsletter